StrideBio, Inc. is a US-based gene therapy company dedicated to developing genetic medicines for rare monogenic diseases. The company's mission is to create best-in-class gene therapies for individuals with life-threatening conditions. StrideBio aims to lead the evolution of gene therapy through superior drug development, high industry standards, and extraordinary integrity, driven by an innovative team that translates scientific advancements into life-prolonging treatments.
StrideBio has made significant strides in the field of genetic medicine, focusing on pioneering therapies that address unmet medical needs. The company's commitment to excellence and innovation has positioned it as a key player in the gene therapy landscape. Through its cutting-edge research and development efforts, StrideBio continues to impact the lives of patients with rare genetic disorders, contributing to the advancement of medical science and therapeutic options.
